{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:19:22Z","timestamp":1791433162277,"version":"4.3.3"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404402"],"award-info":[{"award-number":["82404402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["KYYB202210"],"award-info":[{"award-number":["KYYB202210"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["KYZD202204"],"award-info":[{"award-number":["KYZD202204"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118253","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:18:27Z","timestamp":1760048307000},"page":"118253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A double-edged sword of neo-substrate degradation in PROTACs"],"prefix":"10.1016","volume":"301","author":[{"given":"Zihan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengze","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chixiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-8380","authenticated-orcid":false,"given":"Shenxin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118253_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajh.21610","article-title":"Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis","volume":"85","author":"Lacy","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.118253_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjc.6602774","article-title":"Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide","volume":"93","author":"Bartlett","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118253_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2014.0050","article-title":"IMid-based regimens in patients with myeloma","volume":"12","author":"Khorana","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejmech.2025.118253_bib4","first-page":"1074","article-title":"Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond","volume":"110","author":"Teoh","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118253_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168572","article-title":"Immunomodulatory drugs for the treatment of B cell malignancies","volume":"22","author":"Ioannou","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118253_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118253_bib7","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118253_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117683","article-title":"Crbn-based molecular glues: breakthroughs and perspectives","volume":"104","author":"An","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib9","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.118253_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118253_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118253_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2025.118253_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118253_bib14","doi-asserted-by":"crossref","first-page":"13169","DOI":"10.1021\/acs.jmedchem.5c00783","article-title":"Research progress in targeting GSPT1: molecular glues, bifunctional degraders, and antibody-enabled molecular glues for cancer therapy","volume":"68","author":"Cheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41419-019-1562-9","article-title":"The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in multiple Myeloma: modulation by Bromodomain and extra-terminal (BET) protein inhibitors","volume":"10","author":"Abruzzese","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118253_bib16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","article-title":"SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate","volume":"14","author":"Matyskiela","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118253_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118253_bib18","doi-asserted-by":"crossref","first-page":"20682","DOI":"10.1021\/acs.jmedchem.4c02251","article-title":"Discovery and optimization of First-in-Class molecular glue degraders of the WIZ transcription factor for fetal hemoglobin induction to treat sickle cell disease","volume":"67","author":"Kerrigan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.adk6129","article-title":"A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction","volume":"385","author":"Ting","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118253_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jb\/mvad113","article-title":"Protein degraders - from thalidomide to new PROTACs","volume":"175","author":"Ito","year":"2024","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejmech.2025.118253_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115444","article-title":"Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design","volume":"256","author":"Mi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113749","article-title":"Developments of CRBN-based PROTACs as potential therapeutic agents","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.chembiol.2024.05.004","article-title":"Molecular glues and bifunctional compounds: therapeutic modalities based on induced proximity","volume":"31","author":"Schreiber","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118253_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.ejmech.2025.118253_bib25","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.118253_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118253_bib27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables-the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.ejmech.2025.118253_bib28","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.7150\/ijbs.83026","article-title":"Emerging pharmacotherapeutic strategies to overcome undruggable proteins in cancer","volume":"19","author":"Lu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2025.118253_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111871","article-title":"Targeting the undruggable: recent progress in PROTAC-Induced transcription factor degradation","volume":"17","author":"Jung","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118253_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118253_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092100","article-title":"Targeted protein degradation to overcome resistance in cancer therapies: PROTAC and N-Degron pathway","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118253_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108525","article-title":"Target protein degradation by protacs: a budding cancer treatment strategy","volume":"250","author":"Choudhary","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118253_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400656","article-title":"Drug discovery approaches to target E3 ligases","volume":"26","author":"Rodriguez-Gimeno","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118253_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70009","article-title":"CRBN-PROTACs in cancer therapy: from mechanistic insights to clinical applications","volume":"104","author":"Thapa","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118253_bib36","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.118253_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113906","article-title":"VHL-based PROTACs as potential therapeutic agents: recent progress and perspectives","volume":"227","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116506","article-title":"An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy","volume":"272","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib39","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/14756366.2022.2074414","article-title":"Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents","volume":"37","author":"Wang","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.ejmech.2025.118253_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156001","article-title":"Exploiting E3 ligases for lung cancer therapy: the promise of DCAF-PROTACs","volume":"270","author":"Hussain","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejmech.2025.118253_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current advances and development strategies of orally bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib42","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00424-016-1854-1","article-title":"Cereblon in health and disease","volume":"468","author":"Kim","year":"2016","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ejmech.2025.118253_bib43","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.5c05036","article-title":"Design and application of cereblon-recruiting prodegraders","author":"Chase","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118253_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400365","article-title":"IKZF2 degradation: it's time to take into account it when designing cereblon-based PROTACs","volume":"25","author":"Li","year":"2024","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118253_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104010","article-title":"Strengthening molecular glues: design strategies for improving thalidomide analogs as cereblon effectors and anticancer agents","volume":"29","author":"Nutt","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118253_bib46","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118253_bib47","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118253_bib48","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1021\/acschembio.2c00439","article-title":"Redirecting the neo-substrate specificity of cereblon-targeting PROTACs to helios","volume":"17","author":"Verano","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118253_bib49","doi-asserted-by":"crossref","first-page":"10548","DOI":"10.1021\/acs.jmedchem.3c01823","article-title":"Discovery of KT-413, a targeted protein degrader of IRAK4 and IMiD substrates targeting MYD88 mutant diffuse large B-Cell lymphoma","volume":"67","author":"Weiss","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib50","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118253_bib51","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton's tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib52","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41467-020-17997-6","article-title":"Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118253_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.crchbi.2022.100029","article-title":"Discovery of a potent BTK and IKZF1\/3 triple degrader through reversible covalent BTK PROTAC development","volume":"2","author":"Yu","year":"2022","journal-title":"Curr Res Chem Biol"},{"key":"10.1016\/j.ejmech.2025.118253_bib54","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41422-021-00533-6","article-title":"Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently","volume":"31","author":"Yang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.118253_bib55","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1021\/jacs.4c11930","article-title":"A dual-target and dual-mechanism design strategy by combining inhibition and degradation together","volume":"147","author":"Liu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118253_bib56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118253_bib57","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1021\/acs.jmedchem.2c00807","article-title":"Discovery of a First-in-Class degrader for nuclear receptor binding SET domain protein 2 (NSD2) and Ikaros\/Aiolos","volume":"65","author":"Meng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117381","article-title":"Discovery of highly potent dual GSPT1\/BRD4 degraders with anti-AML activity","volume":"288","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib59","doi-asserted-by":"crossref","first-page":"10268","DOI":"10.1021\/acs.jmedchem.5c00443","article-title":"Rational design of dual degraders by incorporating molecular glue structural features into PROTAC degraders","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117893","article-title":"Discovery of degrader for FLT3, GSPT1 and IKZF1\/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia","volume":"296","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ejmech.2019.05.046","article-title":"Development of selective small molecule MDM2 degraders based on nutlin","volume":"176","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113425","article-title":"Development of MDM2 degraders based on ligands derived from Ugi reactions: lessons and discoveries","volume":"219","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114810","article-title":"Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor","volume":"244","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib64","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2019-131834","article-title":"Bioavailable dual-protein degraders of CK1\u03b1 and transcriptional kinase CDK9 as potential therapeutics for hematological malignancies","volume":"134","author":"Fung","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118253_bib65","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1021\/acs.jmedchem.4c03157","article-title":"Reductive C(sp(2))-C(sp(3)) coupling protocol to enable linker exploration of Cereblon E3-Ligase BRD4 proteolysis-targeting chimeras","volume":"68","author":"Lovato","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib66","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118253_bib67","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118253_bib68","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib69","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"Ito","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.118253_bib70","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118253_bib71","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1021\/acs.jmedchem.3c01521","article-title":"Discovery of potent and selective WDR5 proteolysis targeting Chimeras as potential therapeutics for pancreatic cancer","volume":"66","author":"Yu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117420","article-title":"Design, synthesis, and biological evaluation of novel BTK-targeting proteolysis targeting chimeras (PROTACs) with enhanced pharmacokinetic properties","volume":"289","author":"Lin","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib73","doi-asserted-by":"crossref","first-page":"16388","DOI":"10.1021\/acs.jmedchem.3c01848","article-title":"Design and synthesis of novel cereblon binders for use in targeted protein degradation","volume":"66","author":"Norris","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib74","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118253_bib75","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-selective degradation as a strategy to probe the function of CDK6 in AML","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118253_bib76","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1021\/acsmedchemlett.1c00368","article-title":"Influence of linker attachment points on the stability and neosubstrate degradation of cereblon ligands","volume":"12","author":"Bricelj","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118253_bib77","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib78","article-title":"A degron blocking strategy towards improved CRL4(CRBN) recruiting PROTAC selectivity","volume":"24","author":"Bouguenina","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118253_bib79","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118253_bib80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2019.01.023","article-title":"A novel cereblon modulator for targeted protein degradation","volume":"166","author":"Kim","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib81","doi-asserted-by":"crossref","first-page":"26663","DOI":"10.1002\/anie.202108848","article-title":"Phenyl-glutarimides: alternative cereblon binders for the design of PROTACs","volume":"60","author":"Min","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.118253_bib82","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1021\/acs.jmedchem.4c02709","article-title":"Evaluation of cereblon-directing warheads for the development of orally bioavailable PROTACs","volume":"68","author":"Actis","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib83","doi-asserted-by":"crossref","first-page":"14513","DOI":"10.1021\/acs.jmedchem.3c00851","article-title":"Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs","volume":"66","author":"Steinebach","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118253_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400682","article-title":"Precise modulation of protein degradation by smart PROTACs","volume":"26","author":"Cheng","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118253_bib85","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1021\/acs.accounts.5c00003","article-title":"Strategies for precise modulation of protein degradation","volume":"58","author":"He","year":"2025","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118253_bib86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives","volume":"96","author":"Ito","year":"2020","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.ejmech.2025.118253_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2025.118253_bib88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118253_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2023.12.008","article-title":"Screening for molecular glues - challenges and opportunities","volume":"29","author":"Holdgate","year":"2024","journal-title":"SLAS Discov"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:03:52Z","timestamp":1773147832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":89,"alternative-id":["S0223523425010189"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118253","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A double-edged sword of neo-substrate degradation in PROTACs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118253"}}